ANOVA of Model 1 [General Sta­tis­tics]

posted by Helmut Homepage – Vienna, Austria, 2024-10-03 17:33 (258 d 02:53 ago) – Posting: # 24212
Views: 5,253

Hi BEQool,

❝ … what did you use as an error term (in the denominator) when testing group*treatment effect? MS Error (as for within-subject factors) or Subject(group×sequence) Error (as for between-subject factors)?


Here is the ANOVA of the first simulated study of our Scenario 1:

Response: log(Y)
                       Df      Sum Sq      Mean Sq F value   Pr(>F) 
group                   1 0.171667589 0.1716675892 2.12908 0.151630 
sequence                1 0.339810342 0.3398103421 4.21444 0.046057 *
treatment               1 0.349206911 0.3492069106 4.33098 0.043277 *
group:period            2 0.224598347 0.1122991734 1.39277 0.259120 
group:sequence          1 0.053695040 0.0536950403 0.66594 0.418865 
group:treatment         1 0.252244911 0.2522449107 3.12843 0.083870 .
group:sequence:subject 44 5.173880238 0.1175881872 1.45837 0.107359 
Residuals              44 3.547717653 0.0806299467                   
---
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1

And then …

p.GxT[sim] <- anova(model1)[["group:treatment", "Pr(>F)"]]

 … which is 0.083870. Did we screw up?

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,671 registered users;
31 visitors (0 registered, 31 guests [including 15 identified bots]).
Forum time: 20:26 CEST (Europe/Vienna)

Truth and clarity are complementary.    Niels Bohr

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5